Immunoprophylaxis of Respiratory Syncytial Virus: Global Experience
Author Information
Author(s): Simoes Eric AF
Primary Institution: The University of Colorado School of Medicine and The Children's Hospital
Hypothesis
Can palivizumab effectively reduce RSV-related hospitalizations in high-risk children?
Conclusion
Palivizumab significantly reduces hospitalization rates due to RSV in high-risk infants and children.
Supporting Evidence
- Palivizumab reduced hospitalization rates for RSV infection by 55%.
- Hospitalization rates were 4.8% for palivizumab recipients compared to 10.6% for placebo.
- Hospitalization rates were reduced by 78% in children without bronchopulmonary dysplasia.
Takeaway
Palivizumab is a medicine that helps protect sick babies from a virus that can make them very sick, and it works really well.
Methodology
A randomized, double-blind, placebo-controlled study was conducted with 1502 high-risk infants receiving either palivizumab or placebo.
Limitations
Palivizumab is not effective in children with certain heart conditions and requires monthly intravenous administration, which can be inconvenient.
Participant Demographics
Infants born prematurely or with bronchopulmonary dysplasia, mean age 8 months.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website